Evommune, Inc. (EVMN)
NYSE
Key stats Fiscal year 2025
Income statement
- Revenue
- 13,000,000 85.7%
- Net income
- -68,870,000
- Operating income
- -81,071,000
- Earnings per share
- -11.22
- R&D expense
- 74,042,000
Growth and profitability
- Operating margin
- -623.62
- Net margin
- -529.77
- Return on equity
- -33.50
- Return on assets
- -30.62
- Free cash flow margin
- -589.82
Balance sheet
- Total assets
- 224,946,000
- Total liabilities
- 19,380,000
- Shareholders' equity
- 205,566,000
- Cash and equivalents
- 44,063,000
- Current ratio
- 8.57
Cash flow and ratios
- Operating cash flow
- -76,441,000
- Free cash flow
- -76,676,000
Shareholder returns
- Shares outstanding
- 41,349,860
- Book value per share
- 4.97
Company information
- Headquarters
- Palo Alto, CA
- Exchange
- NYSE
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Evommune, Inc. trades on NYSE under the ticker symbol EVMN. This page brings together its price chart, company profile, key financial figures and technical indicators.